Interleukin 2

DRUG10 trials

Conditions

Acute Myeloid LeukemiaAnkylosing SpondylitisAutoimmune DiseasesAutoimmune HepatitisBehcet's DiseaseChronic Hepatitis CChronic Lymphocytic LeukemiaClear Cell Ovarian Carcinoma

Phase 1

Interleukin-2 Plus Monoclonal Antibody Therapy in Treating Patients With Solid Tumors

CompletedNCT00002994

Alliance for Clinical Trials in OncologyUnspecified Adult Solid Tumor, Protocol Specific

Start: 1997-07-31End: 2002-04-30Updated: 2016-06-28

Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I

TerminatedNCT00277758

Weill Medical College of Cornell UniversityHepatitis C

Start: 2004-03-31End: 2006-08-31Updated: 2008-03-07

Diabetes Islet Preservation Immune Treatment

WithdrawnNCT02586831

Camillo Ricordi and Jay SkylerAutoimmune Diseases, Diabetes Mellitus, Diabetes Mellitus, Type 1 +1

Start: 2024-06-01End: 2024-06-01Updated: 2026-01-15

Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

TerminatedNCT04887259

Lava TherapeuticsAcute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma

Start: 2021-07-12End: 2023-09-06Updated: 2025-01-27

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

RecruitingNCT06321484

Dana-Farber Cancer InstituteClear Cell Ovarian Carcinoma, Endometroid Ovarian Carcinoma, Ovarian Cancer +4

Start: 2024-10-09End: 2031-10-31Target: 18Updated: 2026-03-04

Phase 2

Phase II/III Study Evaluating the Effect of IL-2 on Preservation of the CD4 T-Lymphocytes After Interruption of Antiretroviral Treatment in HIV-Infected Patients With CD4 T-Lymphocyte Count Greater Than 500 Cells/mm3 Who Received Antiretroviral Tx

CompletedNCT00071890

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

Start: 2003-10-31End: 2007-12-31Updated: 2010-10-05

Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients

CompletedNCT00196586

French National Agency for Research on AIDS and Viral HepatitisChronic Hepatitis C, HIV Infections

Start: 2003-04-30End: 2006-11-30Target: 75Updated: 2007-11-16

NY-ESO-1 T Cells in OG Cancer

TerminatedNCT01795976

Fiona ThistlethwaiteOesophageal Cancer

Start: 2014-10-31End: 2017-11-30Updated: 2018-08-07

Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases

CompletedNCT01988506

Assistance Publique - Hôpitaux de ParisAnkylosing Spondylitis, Autoimmune Hepatitis, Behcet's Disease +11

Start: 2014-01-06End: 2021-04-01Updated: 2021-07-20

Phase 4

Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients

CompletedNCT02360592

Tongji HospitalHepatitis B, Chronic

Start: 2013-06-30End: 2017-04-30Updated: 2018-05-09

Cancer Research2025-09-19

Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data

Blood2022-11-1511 citations

686 Mechanism of action of LAVA-051, a bispecific Vγ9Vδ2 T-cell engager (bsTCE), confirmed in the clinical setting

Regular and Young Investigator Award Abstracts2022-11-01

Phase I dose escalation of LAVA-051, a novel bispecific gamma-delta T-cell engager (Gammabody), in relapsed/refractory hematological malignancies.

Journal of Clinical Oncology2022-06-016 citations

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

HemaSphere2022-06-01

Bispecific Vγ9Vδ2-T and Type 1 NKT Cell Engager Lava-051 As First-in-Class Clinical Candidate to Target CD1d Expressing CLL, MM and AML

Blood2021-11-05

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

2018-11-24305 citations

Interleukin 2

Sponsors

Conditions

Phase 1

Phase 2

Phase 4

Related Papers